FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020276240> ?p ?o ?g. }

• W2020276240 endingPage "1522" @default.
• W2020276240 startingPage "1512" @default.
• W2020276240 abstract "Entecavir (ETV) is a potent inhibitor of hepatitis B viral replication, but long‐term therapy may be required. We investigated whether adding on pegylated interferon (Peg‐IFN) to ETV therapy enhances serological response rates. In this global investigator‐initiated, open‐label, multicenter, randomized trial, hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) patients with compensated liver disease started on ETV monotherapy (0.5 mg/day) and were randomized in a 1:1 ratio to either Peg‐IFN add‐on therapy (180 µg/week) from week 24 to 48 (n = 85) or to continue ETV monotherapy (n = 90). Response was defined as HBeAg loss with HBV DNA <200 IU/mL at week 48. Responders discontinued ETV at week 72. All patients were followed until week 96. Response was achieved in 16 of 85 (19%) patients allocated to the add‐on arm versus 9 of 90 (10%) in the monotherapy arm ( P = 0.095). Adjusted for HBV DNA levels before randomized therapy, Peg‐IFN add‐on was significantly associated with response (odds ratio: 4.8; 95% confidence interval: 1.6‐14.0; P = 0.004). Eleven (13%) of the add‐on‐treated patients achieved disease remission after ETV cessation versus 2 of 90 (2%) of those treated with monotherapy ( P = 0.007), which was 79% (11 of 14) versus 25% (2 of 8) of those who discontinued ETV ( P = 0.014). At week 96, 22 (26%) patients assigned add‐on versus 12 (13%) assigned monotherapy achieved HBeAg seroconversion ( P = 0.036). Peg‐IFN add‐on led to significantly more decline in hepatitis B surface antigen, HBeAg, and HBV DNA (all P < 0.001). Combination therapy was well tolerated. Conclusion : Although the primary endpoint was not reached, 24 weeks of Peg‐IFN add‐on therapy led to a higher proportion of HBeAg response, compared to ETV monotherapy. Add‐on therapy resulted in more viral decline and appeared to prevent relapse after stopping ETV. Hence, Peg‐IFN add‐on therapy may facilitate the discontinuation of nucleos(t)ide analogs. (H epatology 2015;61:1512–1522)" @default.
• W2020276240 created "2016-06-24" @default.
• W2020276240 creator A5000989908 @default.
• W2020276240 creator A5003885788 @default.
• W2020276240 creator A5013964835 @default.
• W2020276240 creator A5022079696 @default.
• W2020276240 creator A5026919394 @default.
• W2020276240 creator A5030413648 @default.
• W2020276240 creator A5031051209 @default.
• W2020276240 creator A5043626370 @default.
• W2020276240 creator A5046625776 @default.
• W2020276240 creator A5046750137 @default.
• W2020276240 creator A5054322001 @default.
• W2020276240 creator A5057929739 @default.
• W2020276240 creator A5058639818 @default.
• W2020276240 creator A5061759237 @default.
• W2020276240 creator A5063127492 @default.
• W2020276240 creator A5063203259 @default.
• W2020276240 creator A5082974007 @default.
• W2020276240 creator A5084833963 @default.
• W2020276240 creator A5090026807 @default.
• W2020276240 date "2015-02-27" @default.
• W2020276240 modified "2023-10-18" @default.
• W2020276240 title "Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)" @default.
• W2020276240 cites W1567692243 @default.
• W2020276240 cites W1964039671 @default.
• W2020276240 cites W1964491003 @default.
• W2020276240 cites W1978314081 @default.
• W2020276240 cites W1994650227 @default.
• W2020276240 cites W1998464118 @default.
• W2020276240 cites W2008517556 @default.
• W2020276240 cites W2009474584 @default.
• W2020276240 cites W2024593231 @default.
• W2020276240 cites W2028770751 @default.
• W2020276240 cites W2031317669 @default.
• W2020276240 cites W2037206310 @default.
• W2020276240 cites W2040562731 @default.
• W2020276240 cites W2042565956 @default.
• W2020276240 cites W2042635330 @default.
• W2020276240 cites W2046150771 @default.
• W2020276240 cites W2050571266 @default.
• W2020276240 cites W2084152099 @default.
• W2020276240 cites W2086342653 @default.
• W2020276240 cites W2089153567 @default.
• W2020276240 cites W2091650571 @default.
• W2020276240 cites W2093189109 @default.
• W2020276240 cites W2101032357 @default.
• W2020276240 cites W2102416504 @default.
• W2020276240 cites W2108435608 @default.
• W2020276240 cites W2114785561 @default.
• W2020276240 cites W2146629493 @default.
• W2020276240 cites W2151918606 @default.
• W2020276240 cites W2155246976 @default.
• W2020276240 cites W2328080548 @default.
• W2020276240 doi "https://doi.org/10.1002/hep.27586" @default.
• W2020276240 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25348661" @default.
• W2020276240 hasPublicationYear "2015" @default.
• W2020276240 type Work @default.
• W2020276240 sameAs 2020276240 @default.
• W2020276240 citedByCount "141" @default.
• W2020276240 countsByYear W20202762402015 @default.
• W2020276240 countsByYear W20202762402016 @default.
• W2020276240 countsByYear W20202762402017 @default.
• W2020276240 countsByYear W20202762402018 @default.
• W2020276240 countsByYear W20202762402019 @default.
• W2020276240 countsByYear W20202762402020 @default.
• W2020276240 countsByYear W20202762402021 @default.
• W2020276240 countsByYear W20202762402022 @default.
• W2020276240 countsByYear W20202762402023 @default.
• W2020276240 crossrefType "journal-article" @default.
• W2020276240 hasAuthorship W2020276240A5000989908 @default.
• W2020276240 hasAuthorship W2020276240A5003885788 @default.
• W2020276240 hasAuthorship W2020276240A5013964835 @default.
• W2020276240 hasAuthorship W2020276240A5022079696 @default.
• W2020276240 hasAuthorship W2020276240A5026919394 @default.
• W2020276240 hasAuthorship W2020276240A5030413648 @default.
• W2020276240 hasAuthorship W2020276240A5031051209 @default.
• W2020276240 hasAuthorship W2020276240A5043626370 @default.
• W2020276240 hasAuthorship W2020276240A5046625776 @default.
• W2020276240 hasAuthorship W2020276240A5046750137 @default.
• W2020276240 hasAuthorship W2020276240A5054322001 @default.
• W2020276240 hasAuthorship W2020276240A5057929739 @default.
• W2020276240 hasAuthorship W2020276240A5058639818 @default.
• W2020276240 hasAuthorship W2020276240A5061759237 @default.
• W2020276240 hasAuthorship W2020276240A5063127492 @default.
• W2020276240 hasAuthorship W2020276240A5063203259 @default.
• W2020276240 hasAuthorship W2020276240A5082974007 @default.
• W2020276240 hasAuthorship W2020276240A5084833963 @default.
• W2020276240 hasAuthorship W2020276240A5090026807 @default.
• W2020276240 hasBestOaLocation W20202762401 @default.
• W2020276240 hasConcept C126322002 @default.
• W2020276240 hasConcept C156957248 @default.
• W2020276240 hasConcept C168563851 @default.
• W2020276240 hasConcept C203014093 @default.
• W2020276240 hasConcept C2522874641 @default.
• W2020276240 hasConcept C2775940106 @default.
• W2020276240 hasConcept C2776175608 @default.
• W2020276240 hasConcept C2776461080 @default.

• next